A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia
NCT05353192 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 38
Last updated 2023-02-28
Summary
To Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children with Achondroplasia
Conditions
Interventions
- DRUG
-
Recombinant human growth hormone
Recombinant human growth hormone (15IU/5mg/3ml/bottle)，0.05 mg/kg/d by subcutaneous injection for 52 weeks
Sponsors & Collaborators
-
Children's Hospital of Fudan University
collaborator OTHER -
Tongji Hospital
collaborator OTHER -
Children's Hospital of Nanjing Medical University
collaborator OTHER -
Jiangxi Province Children's Hospital
collaborator OTHER -
Chengdu Women's and Children's Central Hospital
collaborator OTHER -
Shandong Provincial Hospital
collaborator OTHER_GOV -
Shengjing Hospital
collaborator OTHER -
Shanghai Children's Hospital
collaborator OTHER -
Children's Hospital of The Capital Institute of Pediatrics
collaborator OTHER -
West China Second University Hospital
collaborator OTHER -
Changchun GeneScience Pharmaceutical Co., Ltd.
lead INDUSTRY
Principal Investigators
-
Feihong Luo · Children's Hospital of Fudan University
-
Xiaoping Luo · Tongji Hospital
-
Wei Gu · Children's Hospital of Nanjing Medical University
-
Yu Yang · Jiangxi Province Children's Hospital
-
Xinran Cheng · Chengdu Women's and Children's Central Hospital
-
Guimei Li · Shandong Provincial Hospital
-
Ying Xin · Shengjing Hospital of China Medical Hospital
-
Pin Li · Shanghai Children's Hospital
-
Xiaobo Chen · Children's Hospital of The Capital Institute of Pediatrics
-
Jin Wu · West China Second University Hospital
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 2 Years
- Max Age
- 10 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-09-23
- Primary Completion
- 2025-02-28
- Completion
- 2025-02-28
Countries
- China
Study Locations
More Related Trials
-
Growth Retardation In Children With Special Pathological Conditions Or Disease
NCT00163215 ·Status: COMPLETED ·Phase: PHASE3
-
A Study in Children With Achondroplasia
NCT07301463 ·Status: RECRUITING
-
Long Term Study of Genotropin (Somatropin) for Short Children Born Small for Gestational Age (SGA)
NCT01859949 ·Status: COMPLETED ·Phase: PHASE4
-
Extension Study of Pegylated Somatropin to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in Children
NCT03290235 ·Status: UNKNOWN ·Phase: PHASE4
-
Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm
NCT00163189 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Investigate the Safety and Efficacy of Once-weekly PEG-somatropin (GenSci004) in Children With Growth Hormone Deficiency
NCT06024967 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of Recombinant Human Growth Hormone Injection（JINTOPIN AQ）for Short Children With Small for SGA
NCT03221933 ·Status: COMPLETED ·Phase: PHASE2
-
Long-term Efficacy and Safety Evaluation of Growth Hormone in Children in China(CGLS)
NCT06110910 ·Status: RECRUITING
-
A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients With Achondroplasia
NCT01603095 ·Status: COMPLETED
-
Evaluation of Efficacy and Safety of Recombinant Somatroipn in Patients With Growth Hormone Deficiency
NCT02693522 ·Status: COMPLETED ·Phase: PHASE3
-
National Cooperative Growth Study (NCGS) of Optimal Nutropin AQ and Nutropin Dosing in Pubertal Growth Hormone-Deficient (GHD) Patients
NCT00097513 ·Status: COMPLETED
-
Study of the Efficacy and Safety of Somatropin in Japanese Participants With PWS
NCT04697381 ·Status: COMPLETED ·Phase: PHASE3
-
Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children
NCT02314676 ·Status: UNKNOWN ·Phase: PHASE4
-
Treatment With Recombinant Human Growth Hormone (GH) in Children With Short Stature Secondary to a Long Term Corticoid Therapy
NCT00174187 ·Status: TERMINATED ·Phase: PHASE3
-
A Study (Phase 1b/2) of GS3-007a Oral Treatment in Children With Growth Hormone Deficiency (PGHD)
NCT07264595 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Drug Use Investigation of Somatropin for GHD-ADULTS.
NCT00601419 ·Status: COMPLETED
-
Efficiency and Safety Study of Pegylated Somatropin to Treat Growth Hormone Deficiency Children
NCT01342146 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of PEG-somatropin in the Treatment of Children With Idiopathic Short Stature
NCT03221088 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of PEG-somatropin Injection to Treat Children of Turner Syndrome
NCT03189160 ·Status: UNKNOWN ·Phase: PHASE2
-
Special Survey for Long Term Application
NCT01516229 ·Status: COMPLETED
-
The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age
NCT07309562 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of DA-3002 in Children With Idiopathic Short Stature
NCT01786902 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone Injection in Patients With Prader-Willi Syndrome
NCT03554031 ·Status: UNKNOWN ·Phase: PHASE3
-
A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin
NCT01435629 ·Status: COMPLETED
-
Growth Hormone in a Patient With a Dominant-Negative GHR Mutation
NCT05382637 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2